Bristol Myers Squibb IntroducesAnthropic Claude to Accelerate Drug Development

American pharmaceutical giant Bristol Myers Squibb announced on Wednesday a partnership with Anthropic to open up Anthropic's Claude large model to more than 30,000 employees across the company, in order to accelerate the discovery, development, and delivery of new drugs. The company will also introduce Anthropic's programming tool, Claude Code, to assess its potential applications in research, drug development, manufacturing, as well as other business and medical affairs.

Currently, global large-scale pharmaceutical companies are actively engaged in technology cooperation, attempting to leverage the potential of artificial intelligence to unlock drug discovery. Not only Bristol Myers Squibb, but another pharmaceutical giant, Eli Lilly, has also previously partnered with chip manufacturer Nvidia. These industry giants are generally betting on artificial intelligence to improve the success rate of new drug research and development.

Bristol Myers Squibb's Chief Digital and Technology Officer, Greg Meyers, stated that most companies' applications of artificial intelligence are still at the stage of chatbots, while the real value lies in breaking the data that has been locked in data silos for decades, which is also the core purpose of this collaboration. According to McKinsey's forecast report last year, intelligent agents AI that require little human intervention are expected to increase clinical development efficiency by 35% to 45% within the next five years.